FranceFrance

No allergy against the stock market

02.02.2012

Bagneux - DBV Technologies is planning an IPO on Euronext Paris. The French pharmaceutical group specialising in the treatment of allergies was founded in 2002. DBV's proprietary technology Viaskin is used to administer an allergen through the skin without the need of an injection. This epicutaneous process allows significantly to reduce the risk of an allergic reaction. DBV's most advanced product is in Phase II testing to treat peanut allergy in children and adults. The pipeline has two other entries. Milk Viaskin against cow's milk allergies for kids will probably enter a phase II study in 2013, while Viaskin for HDM allergy to dust mites for children will start a phase I study in 2013, the company says. DBV thinks that the three allergies in the pipeline represent a market potential of more than €5bn.

FranceFrance

17.12.2011

Romainville – Cellectis SA has completed its acquisition of Cellartis AB, which provides stem cell-based in vitro R&D tools, in a cash and stock deal valued at €29.1m (US$39.9m). Cellartis shareholders received 1.9 million...

FranceFrance

01.11.2011

Paris – One of the biggest European biotech deals of 2011 is now sealed. As announced in September, the shareholders of French genome engineering specialist Cellectis approved the takeover of Swedish Cellartis, the European...

FranceFrance

26.10.2011

Paris - Sanofi and MS patients can breathe a sigh of relief. At an MS congress in Amsterdam, the company presented impressive results of a phase III trial comparing alemtuzumab with subcutaneous Rebif interferon beta-1a in 581...

FranceFrance

20.10.2011

Paris/Boulder – French drugmaker Servier has secured the rights for two miroRNA drug candidates from US-biotech MiRagen. Both companies clinched a partnership agreement under which Servier would fund the research, development and...

FranceFrance

10.10.2011

Paris/Hyderabad – Sanofi Aventis believes in India. The pharmaceutical company announced the opening a state-of-the-art vaccine manufacturing facility, believed to be Asia's biggest, in March 2012. In the coming years Sanofi will...

FranceFrance

01.10.2011

Paris – Nanobiotix S.A. is entering the clinical stage with its NanoXray nano­particle therapy, which aims to increase the efficacy of radiotherapy without increasing dosage. In mid-September, the French nano­medicine company...

Sweden, FranceFrance

16.09.2011

Paris – For €16.4m in cash and roughly €12m in shares, French genome engineering specialist Cellectis has taken over Swedish Cellartis. Cellartis is the European leader in stem cell-derived cardiomyocytes and hepatocytes. With 62...

Germany, FranceFrance

09.09.2011

Luxembourg - Disorientation reigns in green biotechnology in Europe. Two decisions by the European Court of Justice regarding genetically modified crops point in different directions. On Thursday the judges left the opponents of...

Displaying results 11 to 20 out of 268

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/1/article/no-allergy-against-the-stock-market.html

Image Gallery

Stock list

All quotes

TOP

  • THROMBOGENICS (B)22.00 EUR16.5%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • CLAVIS PHARMA (N)2.18 NOK6.9%

FLOP

  • CYTOS (CH)0.15 CHF-94.8%
  • DIAGENIC (N)0.79 NOK-38.3%
  • PAION (D)3.08 EUR-18.5%

TOP

  • WILEX (D)1.04 EUR79.3%
  • CO.DON (D)3.10 EUR74.2%
  • BIOTECH PHARMACON (N)18.20 NOK56.9%

FLOP

  • CYTOS (CH)0.15 CHF-94.8%
  • BIONOR PHARMA (N)2.08 NOK-48.6%
  • DIAGENIC (N)0.79 NOK-45.9%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6041.2%
  • IXICO (UK)69.50 GBP776.4%
  • PLETHORA (UK)10.75 GBP593.5%

FLOP

  • CYTOS (CH)0.15 CHF-96.5%
  • EVOCUTIS (UK)0.25 GBP-91.9%
  • AGENNIX (D)0.04 EUR-78.9%

No liability assumed, Date: 15.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

Frankfurt am Main

7th DVFA Life Science Conference

White Paper